Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT05389423
Title Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas
Recruitment Not yet recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

non-Hodgkin lymphoma

Therapies

Cyclophosphamide + Doxorubicin + Etoposide + Pomalidomide + Prednisone + Vincristine Sulfate

Cyclophosphamide + Doxorubicin + Etoposide + Pomalidomide + Prednisone + Rituximab + Vincristine Sulfate

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.